Cardinal Health (CAH) Officer Sells 21,367 Shares at $150.53

Insider sale by Cardinal Health officer: The Form 4 shows Deborah Weitzman, identified as an officer (CEO, PSS Segment), sold 21,367 common shares on 08/20/2025 at a weighted average price of $150.53 per share (sales ranged $150.22 to $151.00).

Rhea-AI Filing Summary

Insider sale by Cardinal Health officer: The Form 4 shows Deborah Weitzman, identified as an officer (CEO, PSS Segment), sold 21,367 common shares on 08/20/2025 at a weighted average price of $150.53 per share (sales ranged $150.22 to $151.00). After the reported dispositions she beneficially owned 53,428 shares. The filing notes the weighted-average price and offers to provide detailed per-trade quantities and prices on request. No derivative transactions or additional acquisitions are reported in this Form 4.

Positive

• Transparent disclosure of weighted-average sale price and price range with an offer to provide per-trade details on request
• Compliance with reporting rules via timely Form 4 submission showing the officer's transactions

Negative

• Insider disposition of 21,367 common shares, reducing beneficial ownership to 53,428 shares
• Sale at market prices ($150.22–$151.00), which represents a realized reduction in insider equity stake

Insights

Financial Analyst

TL;DR: Officer sale of 21,367 shares reduces insider stake to 53,428 shares; transaction transparency is intact.

The reported sale is a straightforward insider disposition reported on Form 4. The weighted-average sale price of $150.53 and the disclosed price range provide clear pricing context. There are no reported option exercises or derivative transactions accompanying this filing, so the change reflects a cash sale of common shares rather than conversion activity. Impact on capitalization is likely immaterial absent additional context about total outstanding shares.

Corporate Governance Expert

TL;DR: Compliance appears proper; the sale reduces an officer's holding but the filing provides required disclosure.

The Form 4 includes the customary explanation that the reported price is a weighted average across multiple trades and commits to supply per-trade details if requested, which meets disclosure expectations. The transaction was reported as a direct disposition and the filer signed (via attorney-in-fact). No information here indicates a planned trading arrangement or 10b5-1 plan on the face of the form.

Insider Trade Summary

Net Seller: 21,367 shares

Net Sell 1 txn

Insider WEITZMAN DEBORAH

Role CEO, PSS Segment

Sold 21,367 shs ($3.22M)

Type	Security	Shares	Price	Value
Sale	Common Shares	21,367	$150.53	$3.22M

Holdings After Transaction: Common Shares — 53,428 shares (Direct)

Footnotes (1)

1. F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.22 to $151.00, inclusive. The reporting person undertakes to provide to Cardinal Health, Inc., any security holder of Cardinal Health, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Cardinal Health (CAH) Form 4 report for Deborah Weitzman?

The Form 4 reports that Deborah Weitzman sold 21,367 common shares on 08/20/2025 at a weighted-average price of $150.53, leaving her with 53,428 shares beneficially owned.

Was the sale executed at a single price or multiple prices?

The filing states the price is a weighted average of multiple transactions, with prices ranging from $150.22 to $151.00.

Does the Form 4 show any option exercises or derivative transactions for CAH?

No. The Form 4 lists only non-derivative common share dispositions and shows no derivative securities acquired or disposed of.

Who signed the Form 4 for the reporting person?

The Form 4 is signed by James E. Barnett, Attorney-in-fact for the reporting person on the report.

Is there an indication the sale was part of a 10b5-1 trading plan?

The form does not indicate that the transaction was made pursuant to a 10b5-1 plan; no such plan reference appears in the reported fields.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/20/2025 - 04:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WEITZMAN DEBORAH

(Last) (First) (Middle)

7000 CARDINAL PLACE

(Street)

DUBLIN OH 43017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CARDINAL HEALTH INC [ CAH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, PSS Segment

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/20/2025		S		21,367	D	$150.53(1)	53,428	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.22 to $151.00, inclusive. The reporting person undertakes to provide to Cardinal Health, Inc., any security holder of Cardinal Health, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4.

Remarks:

	/s/ James E. Barnett, Attorney-in-fact	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.